A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease-Reference-Cited by-同舟云学术

A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease

Published:2020-08-01 Issue:5 Volume:16 Page:979-991
ISSN:2629-3269
Container-title:Stem Cell Reviews and Reports
language:en
Short-container-title:Stem Cell Rev and Rep

Author:

Soder Rupal P.,Dawn Buddhadeb,Weiss Mark L.,Dunavin Neil,Weir Scott,Mitchell James,Li Meizhang,Shune Leyla,Singh Anurag K.,Ganguly Siddhartha,Morrison Marc,Abdelhakim Haitham,Godwin Andrew K.,Abhyankar Sunil,McGuirk Joseph^ORCID

Funder

Division of Cancer Epidemiology and Genetics, National Cancer Institute

CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12015-020-10015-8.pdf

Reference99 articles.

1. Gooley, T. A., et al. (2010). Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med, 363(22), 2091–2101. https://doi.org/10.1056/NEJMoa1004383.

2. Bacigalupo, A. (2007). Management of acute graft-versus-host disease. Br J Haematol, 137(2), 87–98. https://doi.org/10.1111/j.1365-2141.2007.06533.x.

3. Lee, S. J. (2005). New approaches for preventing and treating chronic graft-versus-host disease. Blood, 105(11), 4200–4206. https://doi.org/10.1182/blood-2004-10-4023.

4. Wagner, J. E., et al. (2005). Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet, 366(9487), 733–741. https://doi.org/10.1016/s0140-6736(05)66996-6.